person · Reporting owner

Scalzo Richard William

Disclosed activity across 3 companies

Tapewire entity: 35932
SEC CIK: 0001789545

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRESCENT BIOPHARMA, INC.CBIO · Entity 5255	Chief Financial Officer	September 16, 2026	September 18, 2026
Dyne Therapeutics, Inc.DYN · Entity 3948	SVP, Head of Finance & Admin.	March 11, 2025	March 13, 2025
Kaleido Biosciences, Inc.KLDO · Entity 129745	Principal Accounting Officer	October 11, 2019	October 15, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRESCENT BIOPHARMA, INC.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	19,730	Reported balance After 2026-09-16 transaction · row 1 1 source row Row 1 · 2026-09-16 · Sale · Disposed 568 · Balance 19,730 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Dyne Therapeutics, Inc.

Report date March 11, 2025 · Filed March 13, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	122,330	Reported balance After 2025-03-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-03-11 · Sale · Disposed 1,343 · Balance 122,330 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 109,054 unvested RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

F3: Includes 109,054 unvested RSUs.

Kaleido Biosciences, Inc.

Report date October 11, 2019 · Filed October 15, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.28 · Expires 2028-08-15	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-10-11 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: 25% of this option vested and became exercisable on August 18, 2019, with the remainder vesting in 12 equal quarterly installments thereafter.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.78 · Expires 2028-09-04	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-10-11 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: 25% of this option vested and became exercisable on September 5, 2019, with the remainder vesting in 12 equal quarterly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of this option vested and became exercisable on August 18, 2019, with the remainder vesting in 12 equal quarterly installments thereafter.

F2: 25% of this option vested and became exercisable on September 5, 2019, with the remainder vesting in 12 equal quarterly installments thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 16, 2026 Filed Sep 18, 2026 20:02 UTC	CRESCENT BIOPHARMA, INC. CBIO · Entity 5255	SaleOrdinary Shares	568	$17.90	$10,167.20	Disclosure SEC source: 0001628280-26-062705 · wk-form4_1789761760.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,730 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
June 22, 2026 Filed Jun 23, 2026 20:03 UTC	CRESCENT BIOPHARMA, INC. CBIO · Entity 5255	SaleOrdinary Shares	1,112	$17.99	$20,004.88	Disclosure SEC source: 0001628280-26-044890 · wk-form4_1782245034.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,298 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:45 UTC	CRESCENT BIOPHARMA, INC. CBIO · Entity 5255	GrantStock Option (Right to Buy) · Derivative	57,688	$0.00 Strike: $13.21	$0.00	Disclosure SEC source: 0001628280-25-057681 · wk-form4_1766007936.xml · derivative · entry 3 Scalzo Richard William · CIK 0001789545 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,688 Underlying: Ordinary Shares · 57,688 shares Expires 2035-12-15 F2 · derivative.exercise_date: This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:45 UTC	CRESCENT BIOPHARMA, INC. CBIO · Entity 5255	GrantOrdinary Shares	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-057681 · wk-form4_1766007936.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,422 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:45 UTC	CRESCENT BIOPHARMA, INC. CBIO · Entity 5255	GrantOrdinary Shares	14,422	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-057681 · wk-form4_1766007936.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,422 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document
March 11, 2025 Filed Mar 13, 2025 20:08 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,343	$11.38	$15,283.34	Disclosure SEC source: 0000950170-25-038731 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,330 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 109,054 unvested RSUs. Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:06 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	917	$11.83	$10,848.11	Disclosure SEC source: 0000950170-25-035490 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,673 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.73 to $11.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 112,036 unvested RSUs. Read SEC document
February 18, 2025 Filed Feb 18, 2025 22:09 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	2,488	$13.95	$34,707.60	Disclosure SEC source: 0000950170-25-022455 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,590 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.95 to $14.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 114,079 unvested RSUs. Read SEC document
December 11, 2024 Filed Dec 12, 2024 01:40 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,455	$28.12	$40,914.60	Disclosure SEC source: 0000950170-24-135570 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,078 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.76 to $28.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 119,688 unvested RSUs. Read SEC document
December 04, 2024 Filed Dec 6, 2024 21:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock option (right to buy) · Derivative	52,300	$0.00 Strike: $29.44	$0.00	Disclosure SEC source: 0000950170-24-134075 · ownership.xml · derivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,300 Underlying: Common Stock · 52,300 shares Expires 2034-12-03 F3 · derivative.exercise_date: This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028. Read SEC document
December 04, 2024 Filed Dec 6, 2024 21:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantCommon Stock	32,700	$0.00	$0.00	Disclosure SEC source: 0000950170-24-134075 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,533 F1 · shares: Consists of shares of Common Stock issuable under 32,700 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025. F2 · balance_after: Includes 122,669 unvested RSUs. Read SEC document
November 18, 2024 Filed Nov 18, 2024 21:28 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	2,735	$28.20	$77,127.00	Disclosure SEC source: 0000950170-24-127992 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,833 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.00 to $28.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 89,969 unvested RSUs. Read SEC document
September 18, 2024 Filed Sep 19, 2024 20:52 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,390	$34.55	$48,024.50	Disclosure SEC source: 0000950170-24-108153 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,568 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.35 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 95,578 unvested RSUs. Read SEC document
September 11, 2024 Filed Sep 11, 2024 20:13 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,468	$31.89	$46,814.52	Disclosure SEC source: 0000950170-24-105515 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,958 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.59 to $32.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 98,445 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	6,552	$0.00 Strike: $10.88	$0.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · derivative · entry 16 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,394 Underlying: Common Stock · 6,552 shares Expires 2033-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option was granted on November 15, 2023. The shares underlying the option vest over four years in equal monthly installments through November 15, 2027. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	18,750	$0.00 Strike: $10.72	$0.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · derivative · entry 15 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 18,750 shares Expires 2032-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option was granted on December 9, 2022. The shares underlying the option vest over four years in equal monthly installments through December 10, 2026. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	29,792	$0.00 Strike: $8.58	$0.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · derivative · entry 14 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,208 Underlying: Common Stock · 29,792 shares Expires 2032-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on July 11, 2022. The shares underlying the option vest over four years in equal monthly installments beginning on July 1, 2022. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	16,696	$0.00 Strike: $13.12	$0.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · derivative · entry 13 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,348 Underlying: Common Stock · 16,696 shares Expires 2031-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on December 10, 2021. The shares underlying the option vest over four years in equal monthly installments through December 10, 2025. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	34,833	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · derivative · entry 12 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 34,833 shares Expires 2030-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on September 16, 2020. The shares underlying the option vest over four years in equal monthly installments through September 16, 2024. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	3,353	$0.00 Strike: $5.54	$0.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · derivative · entry 11 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,353 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to December 2, 2020. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	6,502	$0.00 Strike: $5.54	$0.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · derivative · entry 10 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,502 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to December 2, 2020. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,700	$32.63	$55,471.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 9 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,426 F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	124,374	$32.14	$3,997,380.36	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 8 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,126 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.62 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	6,552	$10.88	$71,285.76	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 7 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	18,750	$10.72	$201,000.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 6 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	29,792	$8.58	$255,615.36	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 5 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	16,696	$13.12	$219,051.52	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 4 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	34,833	$19.00	$661,827.00	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 3 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	3,353	$5.54	$18,575.62	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	6,502	$5.54	$36,021.08	Disclosure SEC source: 0000950170-24-105123 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
August 19, 2024 Filed Aug 20, 2024 20:28 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	310	$46.00	$14,260.00	Disclosure SEC source: 0000950170-24-099128 · ownership.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,022 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive. Read SEC document
August 19, 2024 Filed Aug 20, 2024 20:28 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	2,442	$45.01	$109,914.42	Disclosure SEC source: 0000950170-24-099128 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,332 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. F3 · balance_after: Includes 101,426 unvested RSUs. Read SEC document
June 11, 2024 Filed Jun 11, 2024 23:28 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,331	$31.34	$41,713.54	Disclosure SEC source: 0000950170-24-072140 · ownership.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,774 F3 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. F5 · balance_after: Includes 107,035 unvested RSUs. Read SEC document
June 10, 2024 Filed Jun 11, 2024 23:28 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,590	$30.23	$48,065.70	Disclosure SEC source: 0000950170-24-072140 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,105 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $30.08 to $30.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document
May 16, 2024 Filed May 18, 2024 01:04 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	462	$28.59	$13,208.58	Disclosure SEC source: 0000950170-24-062077 · ownership.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,695 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive. F4 · balance_after: Includes 110,016 unvested RSUs. Read SEC document
May 16, 2024 Filed May 18, 2024 01:04 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	2,126	$28.20	$59,953.20	Disclosure SEC source: 0000950170-24-062077 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,157 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document
March 11, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,590	$24.99	$39,734.10	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · nonDerivative · entry 7 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,283 F6 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.83 to $25.23, inclusive. F8 · balance_after: Includes 115,624 unvested RSUs. Read SEC document
March 11, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,082	$25.70	$27,807.40	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · nonDerivative · entry 6 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,873 F4 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	17,333	$0.00 Strike: $5.54	$0.00	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · derivative · entry 9 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,333 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	68,919	$0.00 Strike: $5.54	$0.00	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · derivative · entry 8 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,855 Underlying: Common Stock · 68,919 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024 provided that no shares shall vest prior to December 2, 2020. Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	289	$27.33	$7,898.37	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · nonDerivative · entry 5 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,955 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive. Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	55,208	$26.72	$1,475,157.76	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · nonDerivative · entry 4 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,244 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.15, inclusive. Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	30,755	$25.31	$778,409.05	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · nonDerivative · entry 3 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,452 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	17,333	$5.54	$96,024.82	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:57 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	68,919	$5.54	$381,811.26	Disclosure SEC source: 0000950170-24-030482 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 07, 2024 Filed Mar 12, 2024 01:45 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	2,273	$25.85	$58,757.05	Disclosure SEC source: 0000950170-24-029603 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,955 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.84 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 118,605 unvested RSUs. Read SEC document
March 01, 2024 Filed Mar 2, 2024 02:37 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionStock option (right to buy) · Derivative	9,311	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0000950170-24-024298 · ownership.xml · derivative · entry 7 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,311 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document
March 01, 2024 Filed Mar 2, 2024 02:37 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	564	$28.65	$16,158.60	Disclosure SEC source: 0000950170-24-024298 · ownership.xml · nonDerivative · entry 5 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,228 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.55 to $28.83, inclusive. F1 · balance_after: Includes 118,605 unvested RSUs. Read SEC document
March 01, 2024 Filed Mar 2, 2024 02:37 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	8,747	$28.22	$246,840.34	Disclosure SEC source: 0000950170-24-024298 · ownership.xml · nonDerivative · entry 4 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,792 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.48, inclusive. F1 · balance_after: Includes 118,605 unvested RSUs. Read SEC document
March 01, 2024 Filed Mar 2, 2024 02:37 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	Exercise / conversionCommon Stock	9,311	$1.03	$9,590.33	Disclosure SEC source: 0000950170-24-024298 · ownership.xml · nonDerivative · entry 3 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 118,605 unvested RSUs. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.